AHNAK

Across TCGA pan-cancer cohorts, AHNAK mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AHNAK data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AHNAK mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AHNAK expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LSCC, LUAD, and GBM are the cancer types where AHNAK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	II,III,IV	0.640	0.938	<.001	68	view →
LUAD	DFS	Median	III,IV	0.263	0.744	.009	11	view →
GBM	OS	Tertile	All	0.703	0.984	.002	5	view →
CCRCC	OS	Median	IV	0.785	0.123	.009	5	view →
PDAC	OS	Median	II,III,IV	0.953	0.713	.003	3	view →
HNSC	OS	Tertile	IV	0.571	0.810	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AHNAK–LSCC (OS)

Open the LSCC breakdown →